TARS vs. FDMT, VIR, NMRA, ADMA, CGEM, SRRK, BCRX, INBX, AUTL, and FUSN
Should you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include 4D Molecular Therapeutics (FDMT), Vir Biotechnology (VIR), Neumora Therapeutics (NMRA), ADMA Biologics (ADMA), Cullinan Oncology (CGEM), Scholar Rock (SRRK), BioCryst Pharmaceuticals (BCRX), Inhibrx (INBX), Autolus Therapeutics (AUTL), and Fusion Pharmaceuticals (FUSN). These companies are all part of the "biological products, except diagnostic" industry.
Tarsus Pharmaceuticals (NASDAQ:TARS) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, community ranking, profitability, risk, valuation, institutional ownership and dividends.
4D Molecular Therapeutics has higher revenue and earnings than Tarsus Pharmaceuticals. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 11.5% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 7.3% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Tarsus Pharmaceuticals received 8 more outperform votes than 4D Molecular Therapeutics when rated by MarketBeat users. However, 64.71% of users gave 4D Molecular Therapeutics an outperform vote while only 64.06% of users gave Tarsus Pharmaceuticals an outperform vote.
Tarsus Pharmaceuticals has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.94, suggesting that its stock price is 194% more volatile than the S&P 500.
In the previous week, Tarsus Pharmaceuticals had 11 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 20 mentions for Tarsus Pharmaceuticals and 9 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.88 beat Tarsus Pharmaceuticals' score of 0.57 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.
Tarsus Pharmaceuticals currently has a consensus target price of $49.88, indicating a potential upside of 34.80%. 4D Molecular Therapeutics has a consensus target price of $44.22, indicating a potential upside of 72.07%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -436.30%. 4D Molecular Therapeutics' return on equity of -32.58% beat Tarsus Pharmaceuticals' return on equity.
Summary
4D Molecular Therapeutics beats Tarsus Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Tarsus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tarsus Pharmaceuticals Competitors List
Related Companies and Tools
